Market Closed -
Nasdaq
01:30:00 08/05/2024 am IST
|
5-day change
|
1st Jan Change
|
5.68
USD
|
+0.35%
|
|
+9.02%
|
-43.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,502
|
4,335
|
1,796
|
596.6
|
827.4
|
465.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,045
|
3,932
|
1,296
|
159.2
|
400.2
|
213
|
370.4
|
378.7
|
P/E ratio
|
-11
x
|
-35.4
x
|
-9.32
x
|
-2.76
x
|
-5.01
x
|
-2.31
x
|
-2.21
x
|
-2.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
73.1
x
|
47.8
x
|
70.3
x
|
30.3
x
|
10.6
x
|
13.6
x
|
18.7
x
|
7.17
x
|
EV / Revenue
|
50.9
x
|
43.3
x
|
50.7
x
|
8.08
x
|
5.12
x
|
6.21
x
|
14.9
x
|
5.84
x
|
EV / EBITDA
|
-7.56
x
|
-30
x
|
-6.89
x
|
-0.72
x
|
-2.45
x
|
-0.92
x
|
-1.36
x
|
-1.45
x
|
EV / FCF
|
-18.6
x
|
-21
x
|
-7.55
x
|
-0.88
x
|
-2.92
x
|
-1.1
x
|
-1.61
x
|
-1.46
x
|
FCF Yield
|
-5.38%
|
-4.76%
|
-13.3%
|
-114%
|
-34.2%
|
-91.2%
|
-62.1%
|
-68.4%
|
Price to Book
|
6.16
x
|
11.1
x
|
3.28
x
|
1.69
x
|
2.2
x
|
1.85
x
|
4.06
x
|
5.84
x
|
Nbr of stocks (in thousands)
|
50,716
|
61,824
|
67,648
|
67,259
|
81,674
|
82,235
|
-
|
-
|
Reference price
2 |
29.61
|
70.11
|
26.55
|
8.870
|
10.13
|
5.660
|
5.660
|
5.660
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
22/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.53
|
90.73
|
25.54
|
19.71
|
78.12
|
34.3
|
24.82
|
64.89
|
EBITDA
1 |
-138.1
|
-130.9
|
-188.1
|
-219.6
|
-163.1
|
-232.4
|
-272.9
|
-261.2
|
EBIT
1 |
-140.9
|
-134.8
|
-193.1
|
-226
|
-169.2
|
-224.5
|
-256.1
|
-260.1
|
Operating Margin
|
-686.39%
|
-148.61%
|
-756.13%
|
-1,146.26%
|
-216.56%
|
-654.55%
|
-1,031.83%
|
-400.91%
|
Earnings before Tax (EBT)
1 |
-133.7
|
-116
|
-192.5
|
-220.4
|
-153.2
|
-201.3
|
-234.6
|
-245
|
Net income
1 |
-133.7
|
-116
|
-192.5
|
-220.4
|
-153.2
|
-206.3
|
-242.3
|
-248.8
|
Net margin
|
-651.43%
|
-127.82%
|
-753.61%
|
-1,118.26%
|
-196.13%
|
-601.41%
|
-976.21%
|
-383.36%
|
EPS
2 |
-2.680
|
-1.980
|
-2.850
|
-3.210
|
-2.020
|
-2.453
|
-2.561
|
-2.603
|
Free Cash Flow
1 |
-56.16
|
-187
|
-171.8
|
-181.5
|
-136.9
|
-194.2
|
-230.2
|
-259.1
|
FCF margin
|
-273.54%
|
-206.11%
|
-672.49%
|
-920.59%
|
-175.23%
|
-566.12%
|
-927.45%
|
-399.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
22/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6.197
|
12.47
|
6.771
|
6.362
|
0.042
|
6.536
|
9.851
|
2.887
|
5.336
|
60.05
|
7.296
|
5.497
|
5.699
|
14.01
|
7.63
|
EBITDA
1 |
-38.06
|
-40.1
|
-50.75
|
-
|
-
|
-61.87
|
-
|
-
|
-48.65
|
-22.5
|
-60.46
|
-62.23
|
-64.18
|
-
|
-
|
EBIT
1 |
-39.25
|
-41.61
|
-50.75
|
-54.23
|
-57.52
|
-63.45
|
-50.96
|
-44.09
|
-50.16
|
-23.96
|
-55.77
|
-56.84
|
-59.28
|
-54.41
|
-58.1
|
Operating Margin
|
-633.42%
|
-333.7%
|
-749.52%
|
-852.47%
|
-1,36,952.38%
|
-970.72%
|
-517.32%
|
-1,527.33%
|
-940.09%
|
-39.9%
|
-764.29%
|
-1,033.98%
|
-1,040.3%
|
-388.37%
|
-761.53%
|
Earnings before Tax (EBT)
1 |
-39.08
|
-41.44
|
-50.52
|
-53.45
|
-55.73
|
-60.74
|
-49.04
|
-40.29
|
-45.02
|
-18.87
|
-45.17
|
-50.24
|
-52.49
|
-47.81
|
-55.06
|
Net income
1 |
-39.08
|
-41.44
|
-50.52
|
-53.45
|
-55.73
|
-60.74
|
-49.04
|
-40.29
|
-45.02
|
-18.87
|
-46.72
|
-51.36
|
-53.68
|
-50.27
|
-55.06
|
Net margin
|
-630.66%
|
-332.31%
|
-746.05%
|
-840.19%
|
-1,32,680.95%
|
-929.28%
|
-497.78%
|
-1,395.57%
|
-843.68%
|
-31.43%
|
-640.34%
|
-934.28%
|
-941.92%
|
-358.84%
|
-721.64%
|
EPS
2 |
-0.5700
|
-0.6100
|
-0.7400
|
-0.7800
|
-0.8100
|
-0.8800
|
-0.7100
|
-0.5600
|
-0.5500
|
-0.2300
|
-0.5783
|
-0.6252
|
-0.6394
|
-0.5922
|
-0.6040
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
24/02/22
|
04/05/22
|
03/08/22
|
02/11/22
|
22/02/23
|
05/05/23
|
02/08/23
|
03/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
457
|
402
|
500
|
437
|
427
|
252
|
95
|
86.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-56.2
|
-187
|
-172
|
-181
|
-137
|
-194
|
-230
|
-259
|
ROE (net income / shareholders' equity)
|
-53.6%
|
-35.4%
|
-40.6%
|
-48.2%
|
-43.2%
|
-110%
|
-193%
|
-218%
|
ROA (Net income/ Total Assets)
|
-28.8%
|
-21.4%
|
-30.8%
|
-37%
|
-30.2%
|
-83.9%
|
-174%
|
-211%
|
Assets
1 |
464.6
|
540.7
|
625
|
595.9
|
506.7
|
245.8
|
139.6
|
117.9
|
Book Value Per Share
2 |
4.810
|
6.290
|
8.080
|
5.250
|
4.600
|
3.070
|
1.400
|
0.9700
|
Cash Flow per Share
2 |
-
|
-
|
-2.420
|
-2.580
|
-1.790
|
-3.280
|
-3.150
|
-
|
Capex
1 |
6.17
|
7.16
|
7.98
|
4.12
|
4.72
|
5.25
|
5.25
|
4.5
|
Capex / Sales
|
30.04%
|
7.89%
|
31.23%
|
20.89%
|
6.04%
|
15.31%
|
21.15%
|
6.93%
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
22/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
5.66
USD Average target price
15.4
USD Spread / Average Target +172.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.93% | 465M | | +21.74% | 46.81B | | -0.97% | 41.37B | | +47.07% | 41.29B | | -3.52% | 28.87B | | +11.12% | 26.06B | | -19.37% | 19.13B | | +31.18% | 12.39B | | -0.04% | 12.08B | | +0.39% | 11.96B |
Other Biotechnology & Medical Research
|